The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced, “one-click” solution
June 09, 2023 02:16 PM Eastern Daylight Time
OXFORD, England–(BUSINESS WIRE)–Oxford Nanopore Technologies plc (Oxford Nanopore), the company delivering a new generation of nanopore-based molecular sensing technology, and Geneyx, an AI platform for human genetic analysis and interpretation, are aiming to team up to develop the first scalable software solution for the end-to-end analysis and clinical reporting of nanopore sequencing data. The advanced platform will seamlessly empower clinical centres including hospitals, genetic labs and researchers with human whole-genome sequencing data and analysis.
The new software platform, which is anticipated to be commercially available following the completion of a pilot phase, is intended to advance the future clinical use of nanopore sequencing and will be designed to load, visualise and annotate nanopore sequencing data. Once available, it will be of immediate use in newborn screening and the research and characterisation of rare and undiagnosed diseases, providing “one-click” analysis of whole human sequencing data, including actionable genetic variants.
The collaboration will combine Geneyx’s data analysis capabilities with Oxford Nanopore’s human-variation workflow and secure data transfer. The platform will seamlessly integrate with EPI2ME™, Oxford Nanopore’s data analysis solution, which will perform the secondary sequence analysis. The results will then be pushed to the Geneyx cloud and on-site capability, where precise annotation and classification of the variants will be performed, providing a further layer of simplified bioinformatics designed for future clinical use.
The partnership will kick off with pilot projects to evaluate this software solution within third-party sites. The Geneyx solution is currently used by 4,000 active users in 36 countries worldwide.
Gordon Sanghera, CEO, Oxford Nanopore Technologies, commented:
“We are excited to collaborate with Geneyx to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data. Through this seamless integration, customers will benefit from the combined power of nanopore sequencing with Geneyx’s AI-powered analysis for an added layers of insight to support critical workflows such as newborn screening and research into rare disease.”
David Yizhar, CEO, Geneyx commented:
“This collaboration combines Geneyx’s analysis expertise with Oxford Nanopore Technologies groundbreaking sequencing technology. This will enable us to deliver robust and accurate genetic insights to healthcare providers, including a comprehensive genomic solution for Long-Read whole genome sequencing analysis. Together, we will elevate research and diagnostics, empowering patients and researchers seeking answers.”
About Oxford Nanopore Technologies
Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. www.nanoporetech.com